Skip to content

US · CNTN · BIOTECHNOLOGY

Canton Strategic Holdings Inc (CNTN) intrinsic value and stock valuation

$1.21as of 2026-11-21 · Mkt cap 66.63M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Canton Strategic Holdings Inc DCF and intrinsic value

InvestorsCraft values CNTN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CNTN’s statements →

Canton Strategic Holdings Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Red Bank, NJ 07701 cantonstrategic.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-35.92M
20192025
Free cash flow
-$-16.13M
20192025
Total equity
$397.9M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-20.11M-$-12.43M-$-9.46M-$-6.88M-$-3.21M
Net income-$-35.92M-$-12.2M-$-9.32M-$-8.47M-$-2.21M
EPSd-$-1.12M-$-9.38M-$-103.56M-$-282.33M-$-73.67M
Operating cash flow-$-16.13M-$-10.9M-$-7.3M-$-6.56M-$-1.09M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-16.13M-$-10.9M-$-7.3M-$-6.56M-$-1.09M
Total assets$519.2M$3.72M$11M$6.69M$620K
Total debt$0.00$0.00$0.00$0.00$2.17M
Net debt-$-17.03M-$-3.56M-$-10.94M-$-6.51M$2.16M
Total equity$397.9M$1.31M$9.13M$5.54M-$-4.68M
Cash and short-term investments$17M$3.56M$10.9M$6.51M$0.00
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$3.07M$6.39M$3.56M$2.28M$1.84M
Selling, general and administrative expenses$17M$6.04M$5.9M$4.6M$1.37M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$20.1M$12.4M$9.46M$6.88M$3.21M
Cost and expenses$20.1M$12.4M$9.46M$6.88M$3.21M
Interest income$40K$250K$150K$0.00$0.00
Interest expense$30K$10K$20K$1.59M$830K
Depreciation and amortization$20K$0.00$150K$230K$0.00
Ebitda-$-42.05M-$-12.21M-$-9.15M-$-6.65M-$-1.38M
Operating income-$-20.11M-$-12.43M-$-9.46M-$-6.88M-$-3.21M
Total other income/expenses, net-$-22M$240K$140K-$-1.59M$1M
Income before tax-$-42.1M-$-12.2M-$-9.32M-$-8.47M-$-2.21M
Income tax expense-$-6.19M$0.00$0.00$0.00$0.00
Net income-$-35.92M-$-12.2M-$-9.32M-$-8.47M-$-2.21M
Weighted average shares outstanding$32.1M$1.3M$90K$30K$30K
Weighted average diluted shares outstanding$32.1M$1.3M$90K$30K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$17M$3.56M$10.9M$6.51M$0.00
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$17.4M$3.72M$11M$6.69M$620K
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$501.8M$0.00$0.00$0.00$0.00
Total assets$519.2M$3.72M$11M$6.69M$620K
Accounts payable$1.09M$1.09M$910K$950K$1.46M
Short-term debt$0.00$0.00$0.00$0.00$1.39M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.29M$2.41M$1.82M$1.14M$4.53M
Long-term debt$0.00$0.00$0.00$0.00$770K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$117.9M$0.00$0.00$0.00$770K
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$121.2M$2.41M$1.82M$1.14M$5.31M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-72.82M-$-36.9M-$-24.7M-$-15.38M-$-6.91M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$397.9M$1.31M$9.13M$5.54M-$-4.68M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$2.17M
Net debt-$-17.03M-$-3.56M-$-10.94M-$-6.51M$2.16M
Cash flow statement
20252024202320222021
Net income-$-35.92M-$-12.2M-$-9.32M-$-8.47M-$-2.21M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$2.88M$710K$830K$800K$1.24M
Change in working capital$990K$560K$840K-$-570K$1.05M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$220K$180K-$-50K-$-140K$580K
Net cash provided by operating activities-$-16.13M-$-10.9M-$-7.3M-$-6.56M-$-1.09M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-77.57M$0.00$0.00$0.00$0.00
Common stock issued$3.73M$4.19M$12.2M$13.7M$0.00
Common stock repurchased$0.00$0.00$0.00-$-70K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$107.2M$3.53M$11.7M$13.1M$900K
Net change in cash$13.5M-$-7.38M$4.42M$6.51M-$-190K
Cash at end of period$17M$3.56M$10.9M$6.51M$0.00
Operating cash flow-$-16.13M-$-10.9M-$-7.3M-$-6.56M-$-1.09M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-16.13M-$-10.9M-$-7.3M-$-6.56M-$-1.09M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Canton Strategic Holdings Inc

        Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.

        CEO
        Mark Wendland
        Employees
        12
        Beta
        1.44

        Explore

        Frequently asked questions

        What is the intrinsic value of Canton Strategic Holdings Inc (CNTN)?

        InvestorsCraft does not currently publish an intrinsic value for CNTN. How the IC value is calculated.

        Is CNTN undervalued?

        InvestorsCraft does not publish an undervaluation signal for CNTN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.